Quick Answer
Definium Therapeutics, Inc. reported Stockholders Equity of $332.33 million for the year ending 2025.
- Definium Therapeutics, Inc. showed an increase of +37.6% in Stockholders Equity from 2024 to 2025.
- This data is from Definium Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2019 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $180.59 million | Q2 2021: $171.63 million | Q3 2021: $164.27 million | Q1 2022: $136.81 million | Q2 2022: $124.50 million | Q3 2022: $153.59 million | Q1 2023: $130.34 million | Q2 2023: $105.97 million | Q3 2023: $95.98 million | Q1 2024: $196.06 million | Q2 2024: $202.05 million | Q3 2024: $262.19 million | Q1 2025: $222.81 million | Q2 2025: $185.40 million | Q3 2025: $130.60 million.
- Historical annual values: Fiscal year 2025: $332.33 million | Fiscal year 2024: $241.45 million | Fiscal year 2023: $78.13 million | Fiscal year 2022: $150.92 million | Fiscal year 2021: $151.66 million | Fiscal year 2020: $75.87 million | Fiscal year 2019: $4.78 million | Fiscal year 2019: $0.00.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: